Answers are grounded in this paper and cite their sources.
Worldwide, tuberculosis (TB) is among the top five causes of death for women aged 15–44 years [1]. In 2014, an estimated 480 000 of newly reported TB cases were multidrug-resistant (MDR) TB [1]. Pregnancy is a risk factor for reactivation of TB, but data about multidrug-resistant (MDR)-TB in pregnant women are lacking. There are few data about the efficacy and safety of second-line anti-TB drugs during pregnancy for both the mother and the unborn child [2]. One study from Peru showed a mortality rate of 13% in 38 patients and 13% of these 38 patients were lost to follow-up. Five of the pregnancies ended in spontaneous abortions, and one child was stillborn. Data for pregnant women did not differ from the general MDR-TB population in Peru [2]. Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in an MDR-TB patient
No takes yet. Share an insight, caveat, or question.
Kampenhout et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: